Publicacións (664) Publicacións nas que participase algún/ha investigador/a Ver datos de investigación referenciados.

filter_list

2025

  1. A 28-Year Multicenter Cohort Study of Nontuberculous Mycobacterial Lymphadenitis in Children, Spain

    Emerging Infectious Diseases, Vol. 31, Núm. 3, pp. 536-546

  2. A 5-transcript signature for discriminating viral and bacterial etiology in pediatric pneumonia

    iScience, Vol. 28, Núm. 2

  3. A Phase 3B, Open-Label Study to Evaluate the Immunogenicity and Safety of the Quadrivalent Meningococcal Nimenrix® Vaccine When Given to Healthy Infants at 3 and 12 Months of Age

    Infectious Diseases and Therapy, Vol. 14, Núm. 2, pp. 463-481

  4. A diagnostic host-specific transcriptome response for Mycoplasma pneumoniae pneumonia to guide pediatric patient treatment

    Nature communications, Vol. 16, Núm. 1, pp. 673

  5. A phase 3 study of 20-valent pneumococcal conjugate vaccine in healthy toddlers previously vaccinated in infancy with 13-valent pneumococcal conjugate vaccine

    Vaccine, Vol. 53

  6. Corrigendum to “A Phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of V114 compared with PCV13 in healthy infants (PNEU-PED-EU-1)” [Vaccine 41 (2023) 3387–3398, (S0264410X23004280), (10.1016/j.vaccine.2023.04.036)]

    Vaccine

  7. Critical assessment of uncertainty in economic evaluations on influenza vaccines for the elderly population in Spain

    BMC Infectious Diseases, Vol. 25, Núm. 1

  8. Five-Year Immune Persistence of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) and Immunogenicity and Safety of a Booster Dose in Children

    Infectious Diseases and Therapy

  9. Full 2023–24 season results of universal prophylaxis with nirsevimab in Galicia, Spain: the NIRSE-GAL study

    The Lancet Infectious Diseases

  10. Global spatiotemporal dynamics of Mycoplasma pneumoniae re-emergence after COVID-19 pandemic restrictions: an epidemiological and transmission modelling study

    The Lancet Microbe, Vol. 6, Núm. 4

  11. How to improve pertussis vaccination in pregnancy: a European expert review

    Expert Review of Vaccines, Vol. 24, Núm. 1, pp. 175-182

  12. Interferon gene expression declines over time post-COVID infection and in long COVID patients

    Infectious Diseases, Vol. 57, Núm. 1, pp. 35-48

  13. Molecular surveillance in the nirsevimab era: lessons from respiratory syncytial virus breakthrough infections

    The Lancet Infectious Diseases

  14. Novedades de las inmunizaciones en la edad pediátrica

    Pediatria Integral

  15. Procalcitonin use in febrile children attending European emergency departments: a prospective multicenter study

    BMC Pediatrics, Vol. 25, Núm. 1

  16. Safety, tolerability, and immunogenicity of pentavalent meningococcal MenABCWY vaccine in healthy infants: A phase 2b randomized clinical trial

    Human vaccines & immunotherapeutics, Vol. 21, Núm. 1, pp. 2463194

2024

  1. 4CMenB journey to the 10-year anniversary and beyond

    Human Vaccines and Immunotherapeutics, Vol. 20, Núm. 1

  2. A Genome-Wide Association Study of Respiratory Syncytial Virus Infection Severity in Infants

    Journal of Infectious Diseases, Vol. 229, pp. S112-S119

  3. A phase 4, open-label study to evaluate the safety and immunogenicity of DTaP5-HBV-IPV-Hib in children previously vaccinated with DTaP2-HBV-IPV-Hib or DTaP5-HBV-IPV-Hib (V419-016)

    Human Vaccines and Immunotherapeutics, Vol. 20, Núm. 1

  4. Airway and Blood Monocyte Transcriptomic Profiling Reveals an Antiviral Phenotype in Infants With Severe Respiratory Syncytial Virus Infection

    Journal of Infectious Diseases, Vol. 229, pp. S100-S111